References
- Habib HN. Experience and recent contributions in sacral nerve stimulation for voiding in both human and animal. Br J Urol 1967;39:73–83.
- Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev 2009;2:CD004202.
- Sherman ND, Amundsen CL. Current and future techniques of neuromodulation for bladder dysfunction. Curr Urol Rep 2007;8:448–54.
- Spinelli M, Giardiello G, Arduini A, van den Hombergh U. New percutaneous technique of sacral nerve stimulation has high initial success rate: preliminary results. Eur Urol 2003;43:70–4.
- Spinelli M, Giardiello G, Gerber M, Arduini A, van den Hombergh U, Malaguti S. New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience. J Urol 2003;170:1905–7.
- Van Voskuilen AC, Oerlemans DJ, Weil EH, van den Hombergh U, van Kerrebroeck PE. Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int 2007;99:107–10.
- Bannowsky A, Wefer B, Braun PM, Junemann KP. Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test. World J Urol 2008;26:623–6.
- Kessler TM, Burkhard FC, Madersbacher H, Kofler A, Poewe W, Kiss G. Safety of prolonged sacral neuromodulation tined lead testing. Curr Med Res Opin 2008;24:343–7.
- Powell CR, Kreder KJ. Long-term outcomes of urgency–frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures. J Urol 2010;183:173–6.
- Sutherland SE, Lavers A, Carlson A, Holtz C, Kesha J, Siegel SW. Sacral nerve stimulation for voiding dysfunction: one institution's 11-year experience. Neurourol Urodyn 2007;26:19–28.
- van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt AA, Siegel S, Jonas U, Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029–34.
- Malone-Lee J, Wahedna I. Characterisation of detrusor contractile function in relation to old age. Br J Urol 1993;72:873–80.
- Eckhardt MD, van Venrooij GE, Boon TA. Interactions between prostate volume, filling cystometric estimated parameters, and data from pressure–flow studies in 565 men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Neurourol Urodyn 2001;20:579–90.
- Peters KM, Killinger KA, Ibrahim IA, Villalba PS. The relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency–frequency. Neurourol Urodyn 2008;27:775–8.
- Hijaz A, Vasavada SP, Daneshgari F, Frinjari H, Goldman H, Rackley R. Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience. Urology 2006;68:533–7.
- van Voskuilen AC, Oerlemans DJ, Weil EH, de Bie RA, van Kerrebroeck PE. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol 2006;49:366–72.
- Kessler TM, Buchser E, Meyer S, Engeler DS, Al-Khodairy AW, Bersch U, Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol 2007;51:1357–63.
- White WM, Mobley JD III, Doggweiler R, Dobmeyer-Dittrich C, Klein FA. Incidence and predictors of complications with sacral neuromodulation. Urology 2009;73:731–5.
- Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 2009;182:2799–804.
- Aboseif SR, Kim DH, Rieder JM, Rhee EY, Menefee SA, Kaswick JR, Sacral neuromodulation: cost considerations and clinical benefits. Urology 2007;70:1069–73.